Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
β2GPI represents the major antigenic target for antiphospholipid antibodies (aPL), the hallmark of antiphospholipid syndrome (APS). β2GPI contains five homologous domains, with domain I (DI) being identified as the main antigenic epitope for pathogenic anti-β2GPI. Antibodies targeting β2GPI-DI (anti-DI) represent a key pathogenic sub-population of aPL, thus their detection may allow the identification of patients at highest clinical risk. It has been reported that β2GPI in vivo exists in two interconvertible biochemical redox dependent configurations. The reduced form has a circular configuration maintained by interaction between the first and fifth domain thus potentially hiding the epitope on DI, whilst the oxidised protein has an open and linear shape in which the DI is exposed. It is known that the proportion of β2GPI in the oxidised form is elevated in patients with APS. Thus, one hypothesis is that the oxidative state of β2GPI might alter the exposure of neo-epitopes on DI thus providing an antigenic drive for anti-DI antibodies production. In this study we investigated the association between circulating oxidised form of β2GPI and presence of anti-DI in APS patients.
Serum samples from 44 patients who fulfilled the revised classification criteria for APS were tested (38 primary and 6 secondary APS). The samples were screened for IgG anti-DI, anti-β2GPI and anti-cardiolipin (anti-CL). A sandwich ELISA for quantifying total β2GPI levels within serum was performed for all samples. Biochemically reduced β2GPI was detected via labelling free thiols within serum proteins with a biotinylated free-thiol binding reagent and then, via coating on a streptavidin plate, detecting the presence of labelled β2GPI with an anti-β2GPI antibody, based on published methods. For the in vivo studies, male Sprague Dawley rats were injected intravenously with 1 mg of IgG purified pooled from 4 healthy individuals or 2 APS anti-DI positive patients (n=6 rats per IgG pool). Blood samples were collected 24-hour after IgG injection and assayed for reduced β2GPI.
A negative correlation was found between the reduced proportion of β2GPI and IgG anti-DI levels (Spearman r = -0.535, p = 0.0002). Furthermore, the proportion of reduced β2GPI was lower in anti-DI positive than anti-DI negative APS patients (p = 0.0178). The relative amount of reduced β2GPI was no different between patients who were positive or negative for anti-β2GPI (p=0.757) or anti-CL (p=0.062). The reduced proportion of β2GPI was no different within serum samples collected from healthy rats injected with purified anti-DI positive IgG from APS patients versus healthy controls (p=1.000).
This study demonstrates that IgG anti-DI are strongly associated with the oxidative state of β2GPI as compared to anti-CL and anti-β2GPI antibodies. Furthermore, the in vivo injection of APS derived IgG did not affect the redox state of β2GPI in the experimental rat-model employed. Though not proof, this study further supports the hypothesis that epitope exposure on DI of β2GPI defined by the redox state of the protein might affect the antigenic drive of pathogenic anti-DI antibodies.
To cite this abstract in AMA style:Raimondo MG, Pericleous C, Radziszewska A, Borghi MO, Pierangeli SS, Meroni PL, Giles I, Rahman A, Ioannou Y. Oxidation of beta2-Glycoprotein I (beta2-GPI) Associates with the Presence of Antibodies to Domain I of beta2-GPI in Patients with the Antiphospholipid Syndrome but Is Not Affected By the Antibodies in Vivo in a Rat Model [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/oxidation-of-beta2-glycoprotein-i-beta2-gpi-associates-with-the-presence-of-antibodies-to-domain-i-of-beta2-gpi-in-patients-with-the-antiphospholipid-syndrome-but-is-not-affected-by-the-antibod/. Accessed October 24, 2021.
« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/oxidation-of-beta2-glycoprotein-i-beta2-gpi-associates-with-the-presence-of-antibodies-to-domain-i-of-beta2-gpi-in-patients-with-the-antiphospholipid-syndrome-but-is-not-affected-by-the-antibod/